logo-loader
viewMorgan Stanley

Morgan Stanley beats third quarter earnings forecasts on strong wealth management revenue

Morgan Stanley said its sales and trading business faces a subdued environment but third quarter results were buoyed by wealth management and investment banking

Morgan Stanley
Morgan Stanley has impressed investors with its third quarter earnings

Morgan Stanley (NYSE:MS) achieved growth in third quarter earnings and revenue ahead of analysts’ expectations, sending its shares higher.  

The bank reported earnings per share of 93 US cents, compared to 81 US cents in the year-ago period and market forecasts for unchanged results.

READ: Morgan Stanley reports growth in both revenues and earnings per share, beating market expectations

Revenue rose to US$9.2bn from US$8.9bn last year, boosted by growth in wealth management. Analysts had expected revenue of US$9.0bn.

Shares rose 1.35% to US$49.60 each in pre-market trading in the US following the results.

Wealth management net revenue gained to US$4.2bn from US$3.8bn, supported by asset management fee revenues and net interest income.

Trading business faces subdued environment

Investment management net revenue edged up to US$675mln from US$552mln and assets under management grew to US$447bn from US$417bn.

Revenue in the institutional securities division increased to US$4.3bn from US$4.5bn as growth in investment banking offset a declines in sales and trading, and fixed income.

“Our third quarter results reflected the stability our wealth management, investment banking and investment management businesses bring when our sales and trading business faces a subdued environment," said Morgan Stanley chairman and chief executive James Gorman.

Quick facts: Morgan Stanley

Price: 43.69 USD

NYSE:MS
Market: NYSE
Market Cap: $68.84 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Medexus Pharmaceuticals pleased with recent Aptevo BioTherapeutics...

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQB:PDDPF) CEO Ken d’Entremont tells Proactive he's pleased with the value the acquisition of hematology asset IXINITY has provided to Medexus, and that it is well positioned to emerge stronger when the economy reopens after the coronavirus crisis....

15 hours, 49 minutes ago

2 min read